HPV Vaccine Does Not Cause POTS or Premature Ovarian Insufficiency
The HPV vaccine does not cause postural orthostatic tachycardia syndrome (POTS) or premature ovarian insufficiency (POI), and concerns about these side effects should not prevent vaccination.
Evidence on POTS
The most robust evidence comes from a large Danish population-based study of 1.4 million females that found no causal association between HPV vaccination and POTS 1. Using a self-controlled case series design over 10.6 million person-years, the study showed:
- No statistically significant increase in POTS risk following vaccination (rate ratio 0.86,95% CI: 0.48-1.54)
- The composite outcome of all autonomic dysfunction syndromes showed a rate ratio of 0.99 (95% CI: 0.74-1.32)
- While the study cannot formally exclude up to a 32% increased risk, any larger increase is statistically unlikely
The American Autonomic Society issued a position statement in 2020 explicitly stating there are no data to support a causal relationship between HPV vaccination and POTS 2. They note that POTS prevalence in peri-pubertal populations (the same group receiving HPV vaccines) creates temporal association without causality.
A comprehensive 2024 review of 102 vaccine injury compensation cases found that in none of the cases was POTS considered directly caused by a vaccine, despite petitioners' claims 3. The legal proceedings consistently found insufficient evidence for causation, even when expert witnesses were involved.
Important Caveat on POTS
One critical distinction: A 2024 systematic review found that while POTS can occur after COVID-19 vaccination, the risk is 5.35 times higher after SARS-CoV-2 infection compared to vaccination 4. This demonstrates that when vaccine-associated POTS does occur with other vaccines, the disease itself poses far greater risk than immunization.
Evidence on Premature Ovarian Insufficiency
The evidence regarding POI is more nuanced but ultimately does not support causation:
Against causation:
- A 2020 comprehensive review of approximately 60,000 females found insufficient evidence to suggest or support a causal relationship between HPV vaccination and POI 5
- The CDC continues to monitor HPV vaccine safety without identifying POI as a confirmed adverse event 6
Surveillance signals (not causation):
- A 2022 VAERS analysis detected a disproportionality signal with a proportional reporting ratio of 46.1 (95% CI: 31.7-67.2) 7
- A 2020 VAERS data mining study found signals for HPV4 vaccine and POI-related events (amenorrhea, irregular menstruation) 8
Critical Interpretation of VAERS Data
These VAERS signals represent statistical associations in a passive reporting system, not proof of causation. The authors themselves acknowledge:
- VAERS data have "well-known limitations" 7
- Findings "may only be partly attributed to notoriety bias" 7
- Results "only represent statistical association," and "causal relationship needs further investigation" 8
The increase in POI reports after 2006 (from 1.4 to 22.2 cases/year) coincides with vaccine introduction but also with increased media attention and reporting bias—a classic example of the Weber effect in pharmacovigilance.
Clinical Recommendations
Proceed with HPV vaccination according to ACIP guidelines 6:
- Routine vaccination at age 11-12 years
- Catch-up vaccination through age 26 years
- Two-dose schedule if initiated before 15th birthday
- Three-dose schedule if initiated at age 15 or older
When counseling patients concerned about POTS or POI:
- Acknowledge that isolated case reports exist but emphasize that large epidemiologic studies found no causal association
- Explain that temporal association (events occurring after vaccination) does not prove causation
- Note that POTS and menstrual irregularities are relatively common in adolescent females regardless of vaccination status
- Emphasize that HPV vaccination prevents multiple cancers with established mortality benefit
Do not delay or avoid HPV vaccination based on POTS or POI concerns, as the cancer prevention benefits far outweigh theoretical risks that lack epidemiologic support 6, 2, 5.